The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1627
June 28, 2021
View Complete Issue         Table of Contents 2019 
Jatenzo - An Oral Testosterone for Hypogonadism
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Jatenzo - An Oral Testosterone for Hypogonadism
June 28, 2021 (Issue: 1627)
An oral formulation of testosterone undecanoate (Jatenzo – Clarus) has been approved by the FDA for treatment of adult men with conditions associated with a deficiency of endogenous testosterone, such as Klinefelter syndrome, orchiectomy, toxic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Jatenzo - An Oral Testosterone for Hypogonadism
Article code: 1627d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.